Follow the 신테카바이오 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 신테카바이오 has recorded 82 reports. Market capitalisation: €36.6bn. The latest transaction was filed on 15 July 2026 (Purchase). Among the most active insiders: 정종선. The full history is openly available.
82
Insider Decl.
n/a
Thresholds
n/a
43 ops.
Buy Volume
n/a
9 ops.
Sell Volume
23Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,920 of 28,065 companies
29.5
score / 100
Value
7
Quality
52
FCF yld-28%
Earn yld-45%
EV/EBITDA·
ROE-59%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
신테카바이오 is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for the medical field.